PYC Therapeutics Ltd (ASX: PYC) Share Price and News

Price

$1.225

Movement

0.015 (-1.21%)

as at 2 May - Closed (20 mins delayed)

52 Week Range

$0.895 - $2.09

 
1 Year Return

+23.17%

PYC Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $714.49 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 583.26 million
Earnings per share -0.111
Dividend per share N/A
Year To Date Return -10.50%
Earnings Yield N/A
Franking -
Share Price

$1.225

Day Change

0.015 (-1.21%)

52 Week Range

$0.895 - $2.09

Yesterday's Close

$1.24

Today's Open

$1.24

Days Range

$1.22 - $1.28

Volume

290,305

Avg. Volume (1 month)

732,773

Turnover

$361,192

as at 2 May - Closed

PYC Therapeutics Ltd (ASX: PYC)
Latest News

A worried man holds his head and look at his computer.
Share Fallers

Why Arcadium Lithium, IAG, PYC Therapeutics, and Zip shares are falling today

These ASX shares are starting the year in the red.

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Share Market News

Why is the PYC Therapeutics share price up 170% in a year?

The PYC Therapeutics share price has risen 170% this year and 13% this month, following promising results in the development…

Read more »

row of piggy banks with large one receiving injection representing rising Immutep share price
Share Market News

Why the PYC Therapeutics (ASX:PYC) share price is up 11% today

The PYC Therapeutics share price is higher today after the company announced that it has added another drug to its…

Read more »

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
Share Market News

Why the PYC Therapeutics (ASX:PYC) share price is up 9% today

The PYC Therapeutics share price is up 9% today following a promising ASX announcement on the effectiveness of its lead…

Read more »

a woman
Investing

Why Phylogica Limited soared 80% today

Phylogica Limited (ASX:PYC) reports some excellent news

Read more »

PYC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About PYC Therapeutics Ltd

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001 and is headquartered in Nedlands, Australia.

PYC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
01 May 2025 $1.24 $0.07 5.96% 513,068 $1.20 $1.24 $1.17
30 Apr 2025 $1.18 $-0.02 -1.67% 129,843 $1.21 $1.21 $1.18
29 Apr 2025 $1.20 $0.00 0.00% 184,090 $1.21 $1.24 $1.18
28 Apr 2025 $1.20 $0.09 8.07% 513,203 $1.18 $1.22 $1.18
24 Apr 2025 $1.12 $0.09 8.74% 175,019 $1.06 $1.12 $1.06
23 Apr 2025 $1.03 $0.04 4.04% 191,671 $1.00 $1.05 $1.00
22 Apr 2025 $0.99 $-0.04 -3.88% 249,221 $1.02 $1.02 $0.99
17 Apr 2025 $1.03 $-0.02 -1.90% 233,069 $1.06 $1.06 $1.01
16 Apr 2025 $1.06 $-0.03 -2.78% 205,263 $1.07 $1.07 $1.03
15 Apr 2025 $1.08 $0.08 8.00% 219,854 $0.99 $1.08 $0.99
14 Apr 2025 $1.00 $0.02 2.04% 2,554,640 $0.98 $1.00 $0.96
11 Apr 2025 $0.98 $-0.03 -2.96% 518,492 $0.98 $1.01 $0.96
10 Apr 2025 $1.02 $0.02 2.01% 1,109,097 $1.03 $1.06 $1.00
09 Apr 2025 $1.00 $-0.06 -5.69% 702,342 $1.03 $1.05 $0.97
08 Apr 2025 $1.06 $0.03 2.93% 730,514 $1.00 $1.10 $1.00
07 Apr 2025 $1.03 $-0.07 -6.42% 1,428,900 $1.06 $1.08 $0.95
04 Apr 2025 $1.09 $-0.06 -5.22% 3,418,770 $1.13 $1.13 $1.09
03 Apr 2025 $1.15 $-0.03 -2.54% 386,150 $1.18 $1.19 $1.12
02 Apr 2025 $1.18 $-0.01 -0.84% 459,472 $1.23 $1.23 $1.17

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Feb 2025 Alan Tribe Issued 28,000,000 $35,000,000
Rights issue.
17 May 2024 Alan Tribe Buy 50,000,000 $5,250,000
Off-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Alan William Tribe Non-Executive ChairmanNon-Executive Director Apr 2018
Mr Tribe has a background in the accounting profession both in the UK and Australia. Moving into industry he became the Managing Director of a group of companies with interests in natural resources in Australia and overseas. The group also included a technology Group which grew through both successful product development and acquisitions. He was closely involved in establishing subsidiary operations in the USA, UK and Singapore to access markets worldwide. Most recently he was the catalyst for the development of large retail operations in Western and South Australia. Mr Tribe will contribute his experience in commercializing technology internationally.
Dr Rohan Hockings Executive DirectorChief Executive Officer Aug 2016
Dr Hockings spent four years with McKinsey & Company and a further two years in the Private Equity industry before joining PYC Therapeutics. He brings an affinity for conceptual thinking to PYC Therapeutics along with an understanding of the company's technology and its commercialization path. Dr Hockings is a founding principal of a private equity fund active in the acquisition of health care assets within Australia. His previous roles include strategy and operational advisory positions with a global management consulting firm, equity capital markets experience as a solicitor with a national law firm and several appointments as a medical practitioner. Dr Hockings has a special interest in both venture capital and private equity within the healthcare industry. He has worked across both disciplines following an internship at Sir Charles Gairdner Hospital and admission to practice in the Supreme Court of Victoria respectively.
Dr Michael Rosenblatt Non-Executive Director Mar 2021
Dr Rosenblatt is currently a Senior Partner of Flagship Pioneering. Dr Rosenblatt joined Flagship from Merck, where he served as Executive Vice President and Chief Medical Officer from 2009 to 2016. During an earlier period at Merck, he led drug discovery efforts in ophthalmology, molecular biology, bone biology, virology, cancer research, gastroenterology, lipid metabolism and cardiovascular research. He has held appointments as Dean of Tufts University School of Medicine; Robert H. Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; President, Harvard Faculty Dean and Senior Vice President for Academic Programs of Beth Israel Deaconess Medical Center; and Director of the Harvard-MIT Division of Health Sciences and Technology. Dr Rosenblatt has served as a founding scientist, scientific advisory board member or director of more than 12 biopharmaceutical companies. He completed internship, residency and endocrinology training at the Massachusetts General Hospital.
Mr Jason Haddock Non-Executive Director Mar 2021
Mr Haddock has more than 20 years of financial and operational experience in the biopharmaceutical industry and currently serves as a Board Director of Codiak Biosciences, a biotech company developing precision exosome therapeutics. He served as CFO at Array BioPharma, Inc., where he was instrumental in the execution of an oncology-focused research, development and commercialization strategy that culminated in the successful launch of two new drugs and the company ultimately being acquired by Pfizer. Prior, he worked at Bristol-Myers Squibb in a variety of finance, strategic, commercial and business development capacities, including CFO and COO roles for business units in Asia Pacific, Europe and the United States. Mr. Haddock has also served as CFO for ArcherDX as the company was acquired by Invitae to create a global leader in comprehensive cancer genetics and precision oncology.
Mr Kevin R Hart Chief Financial OfficerCompany Secretary Jul 2017
-
Mr Andrew Taylor Company Secretary Jun 2023
-
Kevin R Hart Chief Financial OfficerCompany Secretary
-
Andrew Taylor Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Australian Land Pty Ltd <The Southdown A/C> 621,090,559 13.31%
J P Morgan Nominees Australia Pty Limited 193,174,229 4.14%
Pagham Pty Ltd <The Aintree A/C> 191,896,969 4.11%
Runcton Pty Ltd <The Goodwood A/C> 191,896,969 4.11%
Trexon Pty Ltd <Blackpool Trust A/C> 191,896,969 4.11%
Stockbridge Corporation Pty Ltd <The Ascot A/C> 191,896,968 4.11%
Mccusker Holdings Pty Ltd 185,000,000 3.96%
Citicorp Nominess Pty Limited 172,298,260 3.69%
Sietsma Holdings Pty Ltd <The Sietsma Super Fund A/C> 168,250,000 3.61%
Australian Land Pty Ltd <The Tribe Super Fund A/C> 113,136,364 2.42%
National Nominees Limited 93,129,087 2.00%
HSBC Custody Nominees (Australia) Limited 81,642,806 1.75%
Datamatch Pty Ltd <Paragon Family A/C> 75,000,000 1.61%
Mr Anthony Peter Barton & Mrs Corinne Heather Barton <A P Barton Person S/F A/C> 60,000,000 1.29%
Locca Pty Ltd 52,091,721 1.12%
Masali Pty Ltd 51,500,000 1.10%
Dr Yang Sheng Yeo & Ms Esther Mei Yen Liaw <Papy Family A/C> 51,425,925 1.10%
Mr John Baird 43,500,000 0.93%
Mccusker Foundation Ltd <The Mccusker Charitable A/C> 42,000,000 0.90%
Barton & Barton Pty Ltd 40,000,000 0.86%

Profile

since

Note